HHS Proposes Major Updates to Testosterone Therapy Labels

The Department of Health and Human Services (HHS) has announced plans to revise labeling for testosterone replacement therapy (TRT) products, a move that could enhance access for men experiencing idiopathic and age-related hypogonadism. This change aims to reflect the latest scientific research regarding the safety and effectiveness of TRT, according to HHS Secretary Robert F. Kennedy Jr.

The proposed updates include the removal of restrictions related to age-related hypogonadism, modifications to warnings concerning prostate cancer risk, and adjustments to safety information about benign prostatic hyperplasia (BPH), commonly referred to as an enlarged prostate. “During Men’s Health Month, we are putting science back at the center of men’s healthcare,” Kennedy stated, emphasizing the importance of providing both patients and healthcare providers with clearer information to support informed medical decisions.

The initiative follows a December 2025 meeting of FDA experts, who expressed strong support for increasing access to TRT. Earlier this year, the FDA encouraged manufacturers of TRT products to consider new indications for treating low libido in men with idiopathic hypogonadism, or low testosterone without a known medical cause. Currently, FDA-approved TRT is limited to cases of hypogonadism with identifiable genetic or structural causes.

Federal officials assert that the proposed changes are grounded in an expanding body of evidence indicating that testosterone therapy is safe and effective when properly prescribed and monitored. This could potentially broaden treatment options for many men, while also clarifying risks based on the most current information.

### Key Revisions to TRT Labels

The proposed changes focus on three primary areas: age-related hypogonadism, prostate cancer risk, and BPH. The FDA plans to eliminate the restriction that states testosterone therapy’s safety and effectiveness have not been established for men with age-related hypogonadism, which refers to the natural decline in testosterone levels due to aging.

This limitation was introduced in 2015 amid concerns about possible cardiovascular risks associated with testosterone therapy. However, recent studies, including the TRAVERSE trial involving over 5,200 men, have shown no significant increase in the risk of major cardiovascular events for those receiving TRT.

Experts in men’s health have welcomed the decision, underscoring that testosterone replacement within physiological levels is safe and does not lead to adverse cardiovascular events. However, they caution that maintaining testosterone levels within a normal range is crucial to avoid potential health risks.

### Revised Prostate Cancer Warnings

Another significant aspect of the proposed changes involves the longstanding warnings related to prostate cancer. Current labeling advises against using testosterone therapy in men with existing prostate cancer and suggests that treatment could elevate the risk of developing the disease. Under the new guidelines, testosterone therapy would only be contraindicated for men with metastatic prostate cancer.

Experts have challenged the notion that TRT causes prostate cancer, citing a lack of evidence supporting this claim. They agree that while testosterone may accelerate the growth of existing prostate cancer, it does not initiate the disease.

### Changes to BPH Warnings

The FDA is also revising warnings concerning BPH. Existing labeling cautions that testosterone therapy may exacerbate symptoms of the condition. However, recent clinical data do not support this claim for men with mild to moderate BPH, although caution remains for those with severe symptoms. The updated labeling would continue to advise monitoring for patients with significant BPH symptoms.

Experts assert that testosterone replacement therapy can be safe for men with mild to moderate BPH when they are adequately monitored. Ongoing